Skip to main
CYRX
CYRX logo

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort Inc is positioned for substantial growth, driven by an increasing number of therapies entering the market, particularly in cell and gene therapies, which is expected to boost both commercial revenue and clinical trial activity. The continued rise in gene therapy programs, especially those focused on oncology and rare diseases, indicates strong momentum in the approval and development pipeline of new therapies. This market expansion further solidifies CryoPort's role in the life sciences industry, enhancing its financial prospects across the Americas, Europe, the Middle East and Africa, and Asia Pacific regions.

Bears say

CryoPort faces a challenging financial environment characterized by a quarter-over-quarter decline in start-up funding, which may impact its growth potential within the life sciences sector. Additionally, there is a notable slowdown in demand for critical products such as MVE freezers, indicating potential difficulties in driving revenue from its Life Sciences Products segment. This combination of reduced funding and declining product demand contributes to a negative outlook for CryoPort's stock performance moving forward.

CryoPort (CYRX) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Buy based on their latest research and market trends.

According to 9 analysts, CryoPort (CYRX) has a Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.